Pasireotide injection (Signifor®)

Signifor (pasireotide) is covered for adults (≥18) with Cushing’s disease when pituitary surgery is not an option or not curative, and for adults with endogenous Cushing’s syndrome who are awaiting surgery or awaiting therapeutic response after radiotherapy; use is excluded for patients <18 or those eligible for curative surgery. Authorization requires prescription by or consultation with an endocrinologist/Cushing specialist, documentation of diagnosis and surgical/awaiting status, dosing records (initial 0.3–0.9 mg SC BID; start 0.3 mg BID and titrate to 0.6 mg BID in Child‑Pugh B), initial approval durations of 4 months (Cushing’s disease and awaiting-surgery/radiotherapy) and 12‑month reauthorization only if clinical response is documented.

"Initial authorization approval duration for Cushing's disease: 4 months."

Sign up to see full coverage criteria, indications, and limitations.